Seven suggestions for successful SGLT2i use in glomerular disease – a standalone CKD therapy?

McQuarrie, E. P., Gillis, K. A. and Mark, P. B. (2022) Seven suggestions for successful SGLT2i use in glomerular disease – a standalone CKD therapy? Current Opinion in Nephrology and Hypertension, 31(3), pp. 272-277. (doi: 10.1097/MNH.0000000000000786) (PMID:35220316)

[img] Text
265210.pdf - Accepted Version



Purpose of review: Recent advances in the world of glomerular diseases have largely focussed on remission induction with immune modulating therapy. It is well recognised that even with the best available treatments, patients with glomerular diseases may have an increased risk of progressive renal and cardiovascular disease. Recent findings: The arrival of large trials looking at the benefits of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in patients with chronic kidney disease (CKD) and diabetes or not has shifted the entire focus of current management and the shift needs to go further. This review summarises the background to these landmark trials and provides practical guidance for implementation of the results in a general nephrology clinic. In sub-group analyses of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) clinical trial, SGLT2i improved renal outcomes in patients with immunoglobulin A (IgA) nephropathy highlighting the potential for this drug class in glomerular disease. We also discuss where the gaps in evidence are and where future trials in glomerular diseases, be they primary or secondary, should be focussed. Summary: The renal community has never before had evidence of this strength upon which to base recommendations for patients with CKD and we should be grasping it with both hands.

Item Type:Articles
Glasgow Author(s) Enlighten ID:Gillis, Dr Keith and McQuarrie, Dr Emily and Mark, Professor Patrick
Authors: McQuarrie, E. P., Gillis, K. A., and Mark, P. B.
College/School:College of Medical Veterinary and Life Sciences > School of Cardiovascular & Metabolic Health
Journal Name:Current Opinion in Nephrology and Hypertension
Publisher:Lippincott, Williams & Wilkins
ISSN (Online):1473-6543
Published Online:25 February 2022
Copyright Holders:Copyright © 2022 Wolters Kluwer Health, Inc.
First Published:First published in Current Opinion in Nephrology and Hypertension 31(3): 272-277
Publisher Policy:Reproduced in accordance with the publisher copyright policy

University Staff: Request a correction | Enlighten Editors: Update this record